Unum Therapeutics Inc (UMRX) Expected to Announce Earnings of -$0.35 Per Share

Share on StockTwits

Brokerages expect that Unum Therapeutics Inc (NASDAQ:UMRX) will announce earnings per share (EPS) of ($0.35) for the current quarter, according to Zacks. Two analysts have made estimates for Unum Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.36) and the highest estimate coming in at ($0.32). The firm is scheduled to issue its next earnings report on Monday, November 12th.

According to Zacks, analysts expect that Unum Therapeutics will report full year earnings of ($1.56) per share for the current financial year, with EPS estimates ranging from ($1.72) to ($1.40). For the next year, analysts expect that the company will report earnings of ($1.53) per share, with EPS estimates ranging from ($1.76) to ($1.39). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Unum Therapeutics.

Unum Therapeutics (NASDAQ:UMRX) last posted its earnings results on Monday, August 13th. The company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.02. The firm had revenue of $1.67 million during the quarter, compared to analysts’ expectations of $2.45 million.

Several analysts have recently weighed in on UMRX shares. Morgan Stanley boosted their target price on Unum Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Thursday, October 11th. Zacks Investment Research downgraded Unum Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Wedbush boosted their target price on Unum Therapeutics from $18.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, August 14th. Finally, Cowen reissued a “hold” rating on shares of Unum Therapeutics in a report on Monday, September 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $20.67.

Shares of Unum Therapeutics stock traded down $0.16 on Friday, hitting $9.65. The stock had a trading volume of 36,522 shares, compared to its average volume of 227,924. Unum Therapeutics has a 52-week low of $9.01 and a 52-week high of $17.66.

In other news, insider Seth Ettenberg sold 11,485 shares of the business’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $12.47, for a total value of $143,217.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Several institutional investors have recently bought and sold shares of UMRX. Cowen Inc. purchased a new stake in shares of Unum Therapeutics in the 2nd quarter valued at about $8,341,000. BlackRock Inc. purchased a new stake in Unum Therapeutics during the 2nd quarter valued at approximately $6,403,000. Point72 Asset Management L.P. purchased a new stake in Unum Therapeutics during the 1st quarter valued at approximately $3,599,000. Platinum Investment Management Ltd. purchased a new stake in Unum Therapeutics during the 1st quarter valued at approximately $2,499,000. Finally, Bank of America Corp DE purchased a new stake in Unum Therapeutics during the 2nd quarter valued at approximately $1,485,000. 51.50% of the stock is owned by institutional investors and hedge funds.

About Unum Therapeutics

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.

See Also: Exchange-Traded Funds (ETFs)

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply